Skip to main content
    T

    Trevi Therapeutics Inc (TRVI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $14.33
    +1.52 (+11.87%)

    Market Cap: $1.83B

    Last updated: Nov 06, 2026 at 4:20 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    73%(22/30)
    Avg Surprise
    -77.19%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.13
    Range$-0.18 - $-0.11
    10 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.13-3.1%
    60d ago$-0.130.0%
    30d ago$-0.130.0%
    7d ago$-0.130.0%
    Current$-0.13
    Revenue Consensus
    $0
    Range$0 - $0
    9 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.16
    Range$-0.26 - $-0.02
    10 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    10 analysts
    Last 12 of 32 reported quarters and 2 upcoming estimates
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$-0.16$-0.26 - $-0.02--10--
    Sep 26EST
    		-$-0.13$-0.18 - $-0.11--10
    0
    1
    30d
    		-
    Jun 26
    Reported Aug 6
    		$-0.11$-0.11$-0.13 - $-0.10+0.00%Beat10
    2
    1
    30d
    		-22.2%
    Mar 26
    Reported May 5
    		$-0.09$-0.07$-0.10 - $-0.05-28.57%Miss10
    4
    0
    30d
    		+0.0%
    Dec 25
    Reported Mar 17
    		$-0.06$-0.10$-0.11 - $-0.08+39.09%Beat9
    4
    0
    30d
    		+45.5%
    Sep 25
    Reported Nov 13
    		$-0.08$-0.10$-0.12 - $-0.09+20.00%Beat8
    1
    0
    30d
    		+38.5%
    Jun 25
    Reported Aug 7
    		$-0.09$-0.10$-0.12 - $-0.08+10.00%Beat8
    1
    0
    30d
    		+25.0%
    Mar 25
    Reported May 8
    		$-0.09$-0.12$-0.15 - $-0.10+25.00%Beat6
    2
    0
    30d
    		+18.2%
    Dec 24
    Reported Mar 18
    		$-0.11$-0.12$-0.13 - $-0.11+6.06%Beat7
    1
    1
    30d
    		-37.5%
    Sep 24
    Reported Nov 6
    		$-0.13$-0.11$-0.13 - $-0.09-18.18%Miss9
    No revisions (30d)
    		-62.5%
    Jun 24
    Reported Aug 8
    		$-0.12$-0.11$-0.11 - $-0.09-9.09%Miss5
    1
    0
    30d
    		-71.4%
    Mar 24
    Reported May 7
    		$-0.11$-0.09$-0.09 - $-0.08-22.22%Miss5
    No revisions (30d)
    		-83.3%
    Dec 23
    Reported Mar 20
    		$-0.08$-0.09$-0.11 - $-0.08+11.11%Beat6
    No revisions (30d)
    		-33.3%
    Sep 23
    Reported Nov 9
    		$-0.08$-0.09$-0.10 - $-0.08+11.11%Beat6
    No revisions (30d)
    		+33.3%

    Key Metrics

    Valuation
    P/E Ratio-42.15EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-19.70%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio37.28xQuick Ratio37.28x
    Trading Statistics
    Beta1.12Avg Volume2.24M
    52-Week High$20.2252-Week Low$9.82

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$13.54
    SMA 20$12.98
    SMA 50$14.27
    SMA 200$14.42
    EMA 10$13.53
    EMA 20$13.45
    EMA 50$14.21
    EMA 200$14.18

    MACD

    Line: -0.08Signal: -0.30Hist: 0.22

    ADX

    ADX: 26.1+DI: 22.1-DI: 18.6

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down40.0
    PSAR$14.49

    Bollinger Bands

    Upper Band$14.46
    Lower Band$11.50
    %B Position2279%(Upper)
    Band Width0.95

    RSI (14-Day)

    Neutral
    57.0

    Momentum Oscillators

    Stoch %K70.6
    Stoch %D73.8
    Williams %R-7.5
    ROC (10d)13.6%
    Momentum1.72
    CCI (20d)106.9
    MFI (14d)67.4

    Volatility Measures

    ATR (14d)$0.77(5.3%)
    StdDev (20d)0.74
    Hist Vol70.1%(High)

    Volume Flow

    VWAP$13.90
    OBV45.9M
    AD Line22.4M
    CMF (20d)-0.174

    Volume Metrics

    Avg Vol (20d)1.9M
    Vol Ratio1.3x
    VWMA (20d)$12.92

    Pivot Points

    R3$14.84
    R2$14.42
    R1$13.62
    Pivot Point$13.20
    S1$12.40
    S2$11.98
    S3$11.18

    Advanced Oscillators

    TSI-3.94
    Ultimate Osc51.9
    KST-37.86

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$146,000$0$0$0$176,000$0
    Cost of Revenue$0$0$31,000$0$0$0$38,000$0$0$0$35,000$0
    Gross Profit$0$0$-31,000$0$0$0$-38,000$0$0$0$-35,000$0
    Operating Expenses$20.51M$14.91M$10.22M$13.92M$13.72M$11.47M$12.24M$14.09M$13.29M$11.91M$8.93M$9.04M
    R&D$15.15M$9.94M$6.19M$10.09M$9.39M$7.81M$9.33M$11.22M$10.02M$8.80M$6.52M$6.32M
    SG&A$5.36M$4.97M$4.03M$3.83M$4.33M$3.66M$2.91M$2.86M$3.27M$3.10M$2.42M$2.72M
    Operating Income$-20,509,000$-14,912,000$-10,220,000$-13,916,000$-13,722,000$-11,470,000$-12,242,000$-14,087,000$-13,289,000$-11,906,000$-8,933,000$-9,045,000
    Interest Income$2.70M$1.70M$1.90M$2.10M$1.41M$1.13M$843,000$826,000$935,000$998,000$1.14M$1.18M
    Interest Expense$0$0$0$0$0$0$1,000$1,000$1,000$1,000$4,000$3,000
    Income Before Tax$-17,816,000$-13,212,000$-8,333,000$-11,817,000$-12,322,000$-10,351,000$-11,398,000$-13,273,000$-12,360,000$-10,910,000$-7,803,000$-7,711,000
    Income Tax Expense$-19,000$-20,000$-17,000$-15,000$-21,000$-11,000$17,000$-31,000$-8,000$-8,000$18,000$-13,000
    Net Income$-17,797,000$-13,192,000$-8,316,000$-11,802,000$-12,301,000$-10,340,000$-11,415,000$-13,242,000$-12,352,000$-10,902,000$-7,821,000$-7,698,000
    EBITDA$-20,995,000$-15,305,000$-10,767,000$-14,178,000$-14,074,000$-11,834,000$-12,499,000$-14,415,000$-13,592,000$-12,253,000$-9,252,000$-9,468,000
    EBIT$-20,512,000$-14,908,000$-10,236,000$-13,918,000$-13,729,000$-11,476,000$-12,240,000$-14,098,000$-13,294,000$-11,907,000$-8,936,000$-8,891,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TRVI

    TRVI Valuation and Fair Value

    P/E
    -42.1x
    P/B
    7.0x
    See GNG's fair value

    TRVI Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -19.7%

    TRVI Competitors

    CompanyTicker
    Galapagos NV ADRGLPG
    Omnicell IncOMCL
    AMN Healthcare Services IncAMN
    Sonida Senior Living IncSNDA
    Certara IncCERT
    Teladoc IncTDOC
    Vir Biotechnology IncVIR
    Intellia Therapeutics IncNTLA

    Sector: Healthcare

    TRVI Analyst Ratings

    Consensus
    Buy
    Analysts
    11
    Strong Buy
    2
    Buy
    9
    Hold
    0
    Sell
    0
    Strong Sell
    0

    TRVI Bull Case vs Bear Case

    Bull case

    • 100.0% of TRVI's analyst ratings are Buy or Strong Buy.

    TRVI Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    6.7%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.13
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 1 down

    TRVI Earnings Date

    TRVI reports Nov 9, 2026, after the close. The date is confirmed.

    TRVI Earnings Call

    The latest TRVI earnings call transcript on file is labeled 2026Q1.

    Read the 2026Q1 transcript

    TRVI ETF Holders

    GNG tracks 11 ETFs that hold TRVI. The largest weights:

    1. State Street SPDR S&P Pharmaceuticals ETF (XPH), 1.63% of the fund
    2. iShares Biotechnology ETF (IBB), 0.09% of the fund
    3. Vanguard Russell 2000 Index Fund ETF Shares (VTWO), 0.04% of the fund
    4. Fidelity Enhanced Small Cap Core ETF (FESM), 0.02% of the fund
    5. Vanguard Health Care Index Fund ETF Shares (VHT), 0.02% of the fund
    Open the ETF Stock Exposure tool for TRVI

    See insider activity

    Frequently Asked Questions About TRVI

    When does TRVI report earnings?

    Trevi Therapeutics Inc (TRVI) is confirmed to report earnings on Nov 9, 2026.

    Does TRVI pay dividends?

    Trevi Therapeutics Inc (TRVI) does not currently pay a regular dividend.

    What is TRVI's market cap?

    Trevi Therapeutics Inc (TRVI) has a market capitalization of $1.83B with a current stock price of $14.33.

    Related stocks

    Sector: Healthcare

    All stocks starting with T

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In